SCHEMBL16747895

SCHEMBL16747895

FC(F)(F)c1ccc(Nc2cncc(-n3c(C(F)(F)F)nc4ccccc43)n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 12/20 0.55
KCNH2 Q12809 1/20 0.47
SCN5A Q14524 1/20 0.47
SCN9A Q15858 1/20 0.47
MAPK1 P28482 1/20 0.44
PIK3CB P42338 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ABCG2 Q9UNQ0 2/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NOD1 Q9Y239 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16739649 0.88 BMI1 (0.54) BMI1KCNH2SCN5ASCN9AABCG2
SCHEMBL16739912 0.88 BMI1 (0.69) BMI1KCNH2SCN5ASCN9AMAPK1
SCHEMBL16740311 0.88 BMI1 (0.54) BMI1KCNH2SCN5ASCN9AABCG2
SCHEMBL16740092 0.87 BMI1 (0.50) BMI1KCNH2SCN5ASCN9AMAPK1
SCHEMBL16748010 0.87 BMI1 (0.53) BMI1KCNH2SCN5ASCN9APIK3CB
SCHEMBL16740083 0.86 BMI1 (0.52) BMI1MAPK1PIK3CBKDM4EALDH1A1
SCHEMBL16740199 0.86 BMI1 (0.55) BMI1KCNH2SCN5ASCN9AMAPK1
SCHEMBL16740114 0.85 BMI1 (0.55) BMI1KCNH2SCN5ASCN9AMAPK1
SCHEMBL18094407 0.85 BMI1 (0.54) BMI1KCNH2SCN5ASCN9AABCG2
SCHEMBL16740094 0.85 BMI1 (0.59) BMI1KCNH2SCN5ASCN9AABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US claimed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US claimed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885KCNH2 3952/4885SCN5A 3115/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B BMI1 1/4885KCNH2 3952/4885SCN5A 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.